-
Introducing PPMD’s Newborn Screening Action Center: A Hub for Advocacy and Education
We are thrilled to announce the launch of PPMD’s Newborn Screening Action Center, a powerful […]
-
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive […]
-
Dyne Therapeutics Announces Positive New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne
Dyne Therapeutics, Inc. has announced positive new clinical data from its ongoing Phase 1/2 DELIVER […]
-
Raising Our Voices This Duchenne Action Month
PPMD is excited to join forces with fellow Duchenne-specific organizations from around the world to […]
-
How I’ve gotten through a busy season in the life of my family
My life has recently been a whirlwind of activity. Now that the dust is finally […]
-
Marking ’30 Days of Strength’ for MD Awareness Month this year
The muscular dystrophy (MD) community is poised to mark National Muscular Dystrophy Awareness Month with […]
-
RAG-18 granted FDA orphan drug status for Duchenne, Becker MD
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to RAG-18, being […]
-
Making memories on what was likely my last family vacation
My wife, Wendy, and I recently enjoyed a beach vacation in North Carolina with our […]
-
Elevidys, one year later: ‘It’s no longer just about coping with DMD’
A little over a year ago, neurologist Sarah Wright administered Elevidys (delandistrogene moxeparvovec-rokl) to then […]
-
Living on campus is new territory for one son with DMD
My past two columns highlighted significant life events: my daughter’s wedding and my return to […]
